➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Harvard Business School
Mallinckrodt
Express Scripts

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Buprenorphine Hydrochloride And Naloxone Hydrochloride patents expire, and when can generic versions of Buprenorphine Hydrochloride And Naloxone Hydrochloride launch?

Buprenorphine Hydrochloride And Naloxone Hydrochloride is a drug marketed by Alvogen Pine Brook, Dr Reddys Labs Sa, Mylan Technologies, Actavis Elizabeth, Amneal Pharms, Ethypharm Usa Corp, Hikma, Lannett Co Inc, Mayne Pharma Inc, Rhodes Pharms, Specgx Llc, Sun Pharm, Teva Pharms Usa, and Wes Pharma Inc. and is included in sixteen NDAs.

The generic ingredient in BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

Drug patent expirations by year for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Recent Clinical Trials for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Milton S. Hershey Medical CenterEarly Phase 1
Virginia Commonwealth UniversityPhase 1/Phase 2
National Institute of Drug AbusePhase 2

See all BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE clinical trials

Pharmacology for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

US Patents and Regulatory Information for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 091149-002 Sep 8, 2014 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
Specgx Llc BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 207000-002 Dec 13, 2017 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Wes Pharma Inc BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 209069-001 Jul 17, 2020 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Sun Pharm BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 201633-001 Aug 5, 2016 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Alvogen Pine Brook BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 205954-001 Jan 24, 2019 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Medtronic
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.